BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-asco-2026-annual-meeting@catalyst-calendar.local
DTSTAMP:20260601T102519Z
DTSTART:20260529T130000Z
DTEND:20260529T133000Z
SUMMARY:ASCO会议肿瘤临床数据集中披露窗口
DESCRIPTION:ASCO 2026于2026年5月29日至6月2日在芝加哥举行。本轮按活动级事件聚合，重点纳入已核验的中国创新药出海与全球肿瘤竞争格局相关主体，包括百利天恒/SystImmune BL-B01D1与ADC管线、康方生物ivonescimab、信达生物IBI363、恒瑞医药、科伦博泰sac-TMT/A400/SKB500、BioNTech/BMS BNT327以及Merck Keytruda/ADC组合数据。\\nImpact score: 87\\nExpected: 市场将围绕PD-1/VEGF、ADC、TROP2、IL-2融合蛋白等方向重估中国创新药出海、授权交易和全球肺癌/乳腺癌竞争格局。\\nAffected: 9926.HK(subject\, mixed\, score 88)\; BNTX(subject\, mixed\, score 86)\; IDYA(subject\, unknown\, score 86)\; 688506.SH(subject\, mixed\, score 86)\; IMNM(subject\, mixed\, score 84)\; COGT(subject\, unknown\, score 82)\\nSources: ASCO Annual Meeting: https://www.asco.org/annual-meeting\\nASCO 2026 call for papers: https://asco.confex.com/asco/2026/cfp.cgi\\nCogent ASCO PEAK press release: https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-oral-presentation-positive-phase-3\\nLegend Biotech ASCO announcement: https://www.stocktitan.net/news/LEGN/legend-biotech-announces-presentations-at-asco-pc24r3vapd97.html\\nTipRanks Legend ASCO summary: https://www.tipranks.com/news/company-announcements/legend-biotech-to-showcase-new-car-t-data-at-asco-2026\\nBioNTech ASCO 2026 press release: https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2026/05/BioNTech-to-Showcase-Progress-Across-Late-Stage-Oncology-Pipeline-at-the-2026-ASCO-Annual-Meeting.html\\nBMS ROSETTA Lung-02 data release: https://news.bms.com/news/corporate-financial/2026/Global-Data-for-BioNTech-and-Bristol-Myers-Squibbs-PD-L1xVEGF-A-Bispecific-Pumitamig-Shows-Encouraging-Efficacy-in-Patients-with-Non-Small-Cell-Lung-Cancer-in-ROSETTA-Lung-02-Trial-2026-TW53rMYYjx/default.aspx\\nIDEAYA ASCO late-breaking announcement: https://www.streetinsider.com/Press%2BReleases/IDEAYA%2BBiosciences%2BAnnounces%2BLate-Breaking%2BAbstract%2BOral%2BPresentation%2Bat%2BASCO%2B2026%2Bto%2BProvide%2BComplete%2BData%2Bfrom%2BPhase%2B23%2BRegistrational%2BTrial%2B%28OptimUM-02%29%2Bof%2BDarovasertib%2Bin%2BCombination%2Bwith%2BCrizoti/26341832.html\\nStockTitan IDEAYA schedule: https://www.stocktitan.net/news/IDYA/ideaya-biosciences-announces-late-breaking-abstract-oral-i3z0urozsiv4.html\\nIDEAYA ASCO late-breaking press release: https://ir.ideayabio.com/2026-04-21-IDEAYA-Biosciences-Announces-Late-Breaking-Abstract-Oral-Presentation-at-ASCO-2026-to-Provide-Complete-Data-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-1L-HLA-A2-Negative-Metastatic-Uveal-Mel\\nBusiness Wire Immunome ASCO selection: https://www.businesswire.com/news/home/20260421372136/en/Immunome-Announces-Oral-Presentation-of-Phase-3-RINGSIDE-Data-at-2026-ASCO-Annual-Meeting\\nBarchart Immunome detailed ASCO data: https://www.barchart.com/story/news/2215252/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting\\nMerck ASCO 2026 oncology update: https://www.nasdaq.com/press-release/merck-highlights-new-long-term-data-and-advancements-across-broad-oncology-portfolio\\nMerck ASCO investor event: https://www.merck.com/events/investor-event-at-asco-2026/\\nMerck ASCO 2026 release: https://www.merck.com/news/merck-highlights-new-long-term-data-and-advancements-across-broad-oncology-portfolio-and-pipeline-research-at-asco-2026/\\nASCO 2026 meeting room application: https://events.jspargo.com/ASCO26/CUSTOM/PDF26/ASCO2026MeetingRoomApp.pdf\\nASCO 2026 registration: https://rah.asco.org/am2026/reg/reg_membertypeselection.asp\\nSystImmune ASCO 2026 release: https://www.prnewswire.com/news-releases/new-clinical-data-for-izalontamab-brengitecan-and-novel-adc-pipeline-to-be-presented-at-asco-2026-302778774.html\\nAkeso ASCO 2026 release: https://www.prnewswire.com/news-releases/over-40-studies-featuring-akesos-innovative-oncology-agents-to-be-presented-at-asco-2026-ivonescimabs-harmoni-6-overall-survival-data-selected-for-plenary-session-302781500.html\\nInnovent ASCO 2026 IBI363 release: https://www.nasdaq.com/press-release/innovent-present-new-clinical-data-ibi363pd-1-il-2a-biased-bispecific-fusion-protein\\nHengrui ASCO 2026 preview: https://www.hengrui.com/media/detail-943.html\\nKelun-Biotech ASCO 2026 oral presentations: https://www.prnewswire.com/news-releases/kelun-biotech-announces-three-clinical-study-results-selected-for-oral-presentations-at-2026-asco-annual-meeting-302749495.html\\nInnovent ASCO 2026 release: https://www.prnewswire.com/news-releases/innovent-to-present-new-clinical-data-of-ibi363pd-1il-2-biased-bispecific-fusion-protein-at-the-2026-asco-annual-meeting-302748980.html\\nKelun-Biotech ASCO 2026 release: https://www.prnewswire.com/apac/zh/news-releases/2026-asco--32026-302749476.html\\nBMS BioNTech ASCO 2026 release: https://investors.bms.com/iframes/press-releases/press-release-details/2026/Global-Data-for-BioNTech-and-Bristol-Myers-Squibbs-PD-L1xVEGF-A-Bispecific-Pumitamig-Shows-Encouraging-Efficacy-in-Patients-with-Non-Small-Cell-Lung-Cancer-in-ROSETTA-Lung-02-Trial/default.aspx\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-asco-2026-annual-meeting
CATEGORIES:conference\,US\,ASCO\,oncology\,clinical-data\,clinical data\,conference\,CAR-T\,CARVYKTI\,DLL3\,investor event\,NSCLC\,bispecific antibody\,BNT327\,BMS-986545\,late-breaking\,Phase 2/3\,uveal melanoma\,darovasertib\,GIST\,Phase 3\,bezuclastinib\,oral abstract\,varegacestat\,desmoid tumors\,Keytruda\,中资创新药\,ADC\,肿瘤临床数据\,PD-1\,VEGF\,创新药出海
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: ASCO会议肿瘤临床数据集中披露窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: ASCO会议肿瘤临床数据集中披露窗口
END:VALARM
END:VEVENT
END:VCALENDAR